Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326805 · ClinicalTrials.gov registry record · Phase 2
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT02326805: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02326805 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 154 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02326805, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well PROSTVAC (prostate-specific antigen \[PSA\]-TRICOM) works in preventing disease progression in patients with prostate cancer undergoing active surveillance. Vaccines made from a person's tumor cells may help the body build an effective immune response to kill tumor cells that express PSA.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Placebo Administration
- BIOLOGICAL Rilimogene Galvacirepvec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2015-06-03 |
| Est. Completion | 2022-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02326805
The ClinicalTrials.gov registry entry for NCT02326805 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02326805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02326805 about?
NCT02326805 is a clinical study titled "PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance". This randomized phase II trial studies how well PROSTVAC (prostate-specific antigen \[PSA\]-TRICOM) works in preventing disease progression in patients with prostate cancer undergoing active surveillance. Vaccines made from a person's tumor cells may help the body build an effective immune response ...
What is the current status of trial NCT02326805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2015-06-03. Estimated completion is 2022-07-20.
What interventions are being tested in trial NCT02326805?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Placebo Administration (OTHER), Rilimogene Galvacirepvec (BIOLOGICAL).
Who is sponsoring clinical trial NCT02326805?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.